| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Travere Therapeutics, Inc.$56.59
-1.88 (-3.22%)
C 51Pipeline Score Fair Value Pharma · Commercial
Market Cap
4.13 B
EPS
-0.50
P/E Ratio
-
Value Trade
79.45 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
127.20 M
R&D Expenses
57.09 M
Operating CF
-40.37 M
Total Assets
555.19 M
Total Liabilities
456.46 M
Equity
98.73 M
D/E Ratio
12,345
2.16 %
Week
13.66 %
1 Month
50.71 %
3 Month
28.04 %
6 Month
141.21 %
5 Year
-92.41 %
All Time
Cash Data
Cash Position
208.95 M
Monthly Burn
13.46 M
Runway
13.5 mo
Burn Trend
SEC Filing
May 4, 2026
Overview
Volume
1.25 M
52 Week Range
13.88 - 48.61
% held by Insiders
2.83 %
% held by Institutions
110.74 %
Enterprise Value
4.19 B
Total Shares
92.23 M
Short %
14.04 %
Float Shares
90.39 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Travere Therapeutics, Inc.
518Total events
5Upcoming
138Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 5
Event history 513
Jun 8, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference 2026 Presentation
Jun 3, 2026
Jun 2, 2026
▲Partnership / LicenseCivorebrutinibCorporate
Exclusive licensing agreement with Everest Medicines for Civorebrutinib
rare kidney diseasessource ↗
May 27, 2026
▲Patent GrantedFILSPARIApprovedIP / Competition
Notice of Allowance from USPTO for patent application directed to methods of using FILSPARI in IgA Nephropathy
IgA Nephropathysource ↗
May 13, 2026
May 7, 2026
▼Equity OfferingCorporate
Priced upsized $475.0 million convertible senior notes offering to refinance 2029 convertible notes
May 7, 2026
◆Oral PresentationFILSPARIApprovedPresentation
Presentation of additional Phase 3 DUPLEX data at NKF Spring Clinical Meeting
FSGSsource ↗
May 5, 2026
◆Equity OfferingCorporate
Proposed convertible senior notes offering to refinance 2029 convertible notes
Apr 13, 2026
◆PDUFA DateFILSPARIApprovedRegulatory Filing
New PDUFA target action date for sNDA in FSGS
focal segmental glomerulosclerosis (FSGS)source ↗
Drug Pipeline Intelligence
C51
Pipeline Score $1.0B
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored0.8x
rNPV / MCap Top 77%
Small Cap (rank 211 of 911)
Percentile RankTravere Therapeutics, Inc. carries a moderate pipeline score (51/100), with $1.6B risk-adjusted pipeline value, led by sparsentan in Immunoglobulin A Nephropathy (Phase 3), across $50B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sparsentan Small molecule | Immunoglobulin A Nephropathy | Phase 3 | NCT03762850 | 50% | $1.5B | ACTIVE NOT_RECRUITING | 478 | SLOW | B (72) | Jul 1, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
FILSPARI PriorityAccelerated | Focal Segmental Glomerulosclerosis (FSGS) | Phase 2/3 | 2025-03-17 | superior and sustained reductions in proteinuria when compared with maximum labeled dose irbesartan Read More | Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS Read More | |
FILSPARI PriorityAccelerated | Focal Segmental Glomerulosclerosis (FSGS) | Phase 2/3 | 2025-03-17 | superior and sustained reductions in proteinuria when compared with maximum labeled dose irbesartan Read More | Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS Read More | |
FILSPARI PriorityAccelerated | Focal Segmental Glomerulosclerosis (FSGS) | Phase 2/3 | 2025-03-17 | superior and sustained reductions in proteinuria when compared with maximum labeled dose irbesartan Read More | Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TVTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TVTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TVTXTravere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
Travere Therapeutics has announced the planned retirement of its Chief Research Officer in 2027. This decision marks a significant transition for the company as it prepares for future leadership changes. The announcement comes as part of the company's ongoing strategic planning efforts.
Read more →TVTXTravere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
Travere Therapeutics presented long-term open-label extension data from the Phase 3 DUPLEX study at the 63rd European Renal Association Congress. This study highlights the ongoing research into treatments for rare kidney diseases. Additionally, the company announced an exclusive licensing agreement with Everest Medicines for Civorebrutinib, a promising BTK inhibitor.
Read more →TVTXTravere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Travere Therapeutics has entered into an exclusive licensing agreement with Everest Medicines for Civorebrutinib, a potential best-in-class BTK inhibitor aimed at treating rare kidney diseases. This partnership may enhance the development and commercialization of the drug in targeted markets. Further details about the agreement and its implications for both companies are yet to be disclosed.
Read more →TVTX▲ +7.8%on this news
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
Travere Therapeutics has received a notice of allowance from the U.S. Patent and Trademark Office for a patent application related to the use of FILSPARI® (sparsentan) in treating IgA nephropathy. This development suggests that the company is making strides in securing intellectual property rights for its therapeutic methods. The patent could enhance the market position of FILSPARI®.
Read more →TVTXEquity Incentive Plan Adopted by the Board of Directors
Travere Therapeutics has adopted a new Equity Incentive Plan, which serves as a successor to previous incentive plans from 2014 and 2015. This plan aims to attract and retain employees, directors, and consultants by offering various stock awards. The Board of Directors will oversee the plan's administration and is empowered to amend the plan as needed. This strategic move is expected to support the company's long-term growth and success.
Read more →TVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 12, 2026
Travere Therapeutics announced the granting of inducement equity grants to four new employees on May 10, 2026. These grants include stock options and restricted stock units (RSUs) totaling 48,800 shares. The stock options have a 10-year term and vest over four years, while the RSUs also vest over four years. This move is in accordance with Nasdaq Listing Rule 5635(c)(4).
Read more →TVTXTravere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes 2026-05-05 SAN DIEGO - (BUSINESWIRE) - Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, su
Travere Therapeutics, Inc. has announced a planned offering of $400 million in convertible senior notes due 2032, subject to market conditions. The company intends to utilize part of the proceeds to repurchase a segment of its existing convertible notes due 2029. Additionally, the offering could be expanded by $60 million if underwriters exercise their option for over-allotments. However, uncertainties regarding the repurchase amount and market conditions may impact the overall execution of the offering.
Read more →TVTXTravere Therapeutics to Participate at Upcoming Investor Conferences - May 7, 2026
Travere Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including the BofA Securities 2026 Health Care Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. Presentations will be accessible via live webcasts, with replays available for 30 days. This engagement highlights the company's commitment to the rare disease community.
Read more →TVTXTravere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Travere Therapeutics has announced an upsized offering of $475 million in convertible senior notes. This move is aimed at refinancing existing convertible notes due in 2029. The offering reflects the company's strategy to manage its debt and optimize its capital structure.
Read more →TVTXTravere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Travere Therapeutics has announced a proposed offering of convertible senior notes aimed at refinancing its 2029 convertible notes. This move is part of the company's financial strategy to manage its debt obligations effectively. Further details regarding the terms and conditions of the offering are expected to be released soon.
Read more →TVTXInvestors Media 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Reports First Quarter 2026 Financial Results FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in
Travere Therapeutics reported its first quarter 2026 financial results, highlighting significant growth due to FILSPARI's success. The company achieved record new patient start forms in IgAN and an impressive 88% year-over-year increase in net product sales. Additionally, FILSPARI received FDA approval for treating FSGS, expanding its potential patient base. However, the company also reported a net loss despite improved financials compared to last year.
Read more →TVTXTravere Therapeutics Reports First Quarter 2026 Financial Results
Travere Therapeutics has reported its financial results for the first quarter of 2026. The article provides insights into the company's performance during this period. However, specific details regarding revenue, expenses, or strategic initiatives are not included.
Read more →TVTXTravere Therapeutics to Report First Quarter 2026 Financial Results
Travere Therapeutics, Inc. will report its first quarter 2026 financial results on May 4, 2026, after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a business update. Archived access to the call will be available for 30 days.
Read more →TVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 14, 2026
Travere Therapeutics announced the granting of inducement equity grants to five new employees, totaling 17,420 restricted stock units (RSUs). These RSUs, granted outside the company's 2018 Equity Incentive Plan, will vest over four years, contingent on the employees' continued service. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to expanding its workforce.
Read more →TVTX▲ +37.2%on this newsshared move
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
Travere Therapeutics has received full FDA approval for FILSPARI (sparsentan), marking it as the first and only approved treatment for focal segmental glomerulosclerosis (FSGS) in patients aged 8 and older without nephrotic syndrome. The approval significantly expands treatment options for over 100,000 patients in the U.S. The Phase 3 DUPLEX Study showed FILSPARI's effectiveness in reducing proteinuria, with a favorable safety profile. The company plans to make FILSPARI available for immediate prescription by nephrologists.
Read more →TVTXTravere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Travere Therapeutics has reported its financial results for the fourth quarter and full year of 2025. Notably, the company announced the full FDA approval of FILSPARI® (sparsentan), marking it as the first and only approved treatment for Focal Segmental Glomerulosclerosis (FSGS). This approval is a significant milestone for the company and its product portfolio.
Read more →TVTX▲ +5.1%on this newsshared move
Investors Media 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results U.S. net product sales of FILSPARI reached $103
Travere Therapeutics reported strong financial results for the fourth quarter and full year 2025, with U.S. net product sales of FILSPARI reaching $103 million. This figure reflects a 108% increase from the prior year. The company is positioned for potential success with ongoing drug approvals, including a PDUFA target action date of April 13, 2026, for FILSPARI in focal segmental glomerulosclerosis (FSGS). Additionally, enrollment activities have resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (HCU), indicating continued momentum in their business strategy.
Read more →TVTXTravere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
Travere Therapeutics is set to announce its financial results for the fourth quarter and full year of 2025. The report will include details on inducement grants made under Nasdaq listing rule 5635(c)(4). This announcement reflects the company's commitment to transparency and compliance with regulatory standards.
Read more →TVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 11, 2026
Travere Therapeutics announced the granting of inducement equity grants to ten new employees, totaling 49,200 restricted stock units (RSUs). These grants, made outside of the company's 2018 Equity Incentive Plan, are intended to attract new talent in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, promoting long-term commitment from the new hires.
Read more →TVTX▼ -7%on this news
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
Travere Therapeutics, Inc. will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. The event will feature a live webcast accessible via the company's investor page, with a replay available for 30 days post-event. This engagement underscores Travere's focus on addressing urgent treatment needs in rare diseases.
Read more →TVTXTravere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
Travere Therapeutics announced that the FDA has extended the review period for its supplemental New Drug Application for FILSPARI (sparsentan) in treating focal segmental glomerulosclerosis (FSGS) to April 13, 2026. This extension follows the submission of additional data requested by the FDA to clarify the drug's clinical benefits. FILSPARI, if approved, would be the first medication indicated for FSGS, a serious kidney disorder.
Read more →TVTX▼ -14.6%on this newsshared move
Travere Therapeutics Provides Corporate Update and 2026 Outlook
Travere Therapeutics reported strong preliminary financial results for Q4 2025, with expected net product sales of approximately $127 million. The company is preparing for the potential launch of FILSPARI in FSGS and plans to restart the Phase 3 HARMONY Study for pegtibatinase in early 2026. Despite positive developments, the financial results are unaudited and may change.
Read more →TVTXInvestors Media 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Provides Corporate Update and 2026 Outlook U.S. FILSPARI reaches all-time highs of 908 new PSFs and net pro
Travere Therapeutics provided an optimistic corporate update highlighting substantial growth for FILSPARI, with Q4 2025 U.S. net sales reaching approximately $103 million and 908 new patient registrations. The company is preparing for a potential commercial launch of FILSPARI in treating Focal Segmental Glomerulosclerosis (FSGS) pending approval. Moreover, the pivotal Phase 3 HARMONY Study of pegtibatinase is set to restart in Q1 2026, indicating positive pipeline advancements. Overall, Travere Therapeutics is poised for continued growth and innovation in addressing rare diseases.
Read more →TVTX▼ -6.1%on this news
Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Travere Therapeutics, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Eric Dube, Ph.D., will lead the presentation, which will be available via a live webcast. This event underscores Travere's commitment to addressing the urgent needs of patients with rare diseases.
Read more →TVTXInvestors Media 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Reports Third Quarter 2025 Financial Results U.S. net product sales of FILSPARI (sparsentan) grew 155% year
Travere Therapeutics released its third quarter 2025 financial results, reporting a 155% increase in FILSPARI sales, reaching $90.9 million. The total revenue for the quarter was $164.9 million, bolstered by a $40 million market access milestone. The company anticipates potential FDA approval for FILSPARI for FSGS in early 2026, further strengthening its market position. Additionally, recent clinical guidelines recommend FILSPARI for earlier use in treating IgAN, highlighting its efficacy in clinical trials.
Read more →TVTXInvestors Media 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Reports Second Quarter 2025 Financial Results U.S. net product sales of FILSPARI (sparsentan) grew 165% yea
Travere Therapeutics reported robust financial results for Q2 2025, with U.S. net product sales of FILSPARI increasing 165% year-over-year to $71.9 million. The company's total revenue reached $114.4 million, supported by a significant milestone payment. Looking ahead, Travere aims for FDA approval of FILSPARI for FSGS by January 2026, which could position it as the first approved therapy for this condition. Additionally, the company is making progress with their research pipeline, specifically in IgAN and classical HCU, despite reporting a net loss for the quarter.
Read more →TVTXInvestors Media 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Reports First Quarter 2025 Financial Results Submitted sNDA seeking full approval of FILSPARI (sparsentan)
Travere Therapeutics reported its first quarter 2025 financial results, highlighting significant net product sales growth of FILSPARI, which reached $55.9 million. The company has submitted a supplemental NDA for FILSPARI to seek full approval for FSGS, with an expected PDUFA date of August 28, 2025. Additionally, FILSPARI has transitioned to full approval in the EU and UK for IgAN, further increasing market access. Overall, Travere is positioned for sustainable growth despite reporting a net loss this quarter.
Read more →TVTX▲ +5.8%on this news
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS). This submission is based on positive results from the Phase 3 DUPLEX and Phase 2 DUET studies, which showed significant efficacy in reducing proteinuria. If approved, FILSPARI could be the first FDA-approved treatment for FSGS, addressing a critical unmet need in kidney disease management.
Read more →TVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics announced inducement equity grants for five new employees, totaling 77,200 shares. This includes stock options and restricted stock units, granted outside of the company's 2018 Equity Incentive Plan. The grants are designed to attract talent and align employee interests with the company's performance.
Read more →TVTXTravere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics, Inc. will participate in several investor conferences in March 2025, including the TD Cowen 45th Annual Health Care Conference and the Leerink Partners Global Biopharma Conference. The company aims to enhance investor engagement and provide updates on its initiatives in rare disease therapies. Live webcasts of these presentations will be available on their investor website.
Read more →TVTX▼ -6.8%on this newsshared move
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Travere Therapeutics reported strong financial results for Q4 and full year 2024, with net product sales of FILSPARI reaching $50 million in Q4 and $132 million for the year. The company plans to submit a supplemental New Drug Application (sNDA) for FILSPARI for FSGS by the end of Q1 2025. Despite increased R&D expenses, the company remains optimistic about its growth trajectory and product pipeline.
Read more →TVTXInvestors Media 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results Company to submit sNDA around the end of 1Q 202
Travere Therapeutics has reported significant financial results for Q4 and full year 2024, highlighted by strong net product sales of FILSPARI totaling $50 million in Q4. The company received full FDA approval for FILSPARI for treating IgAN, enhancing its market presence and physician trust. Plans are now in place to submit a supplemental New Drug Application (sNDA) for FILSPARI regarding FSGS in early 2025, aiming to expand its therapeutic indications. Additionally, improvements in operational efficiencies are noted, although increased R&D and lower other income may warrant further scrutiny.
Read more →TVTXTravere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Travere Therapeutics, Inc. announced that it will report its fourth quarter and full year 2024 financial results on February 20, 2025. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a business update. This event highlights the company's ongoing engagement with investors and commitment to transparency regarding its financial performance.
Read more →TVTX▲ +12.6%on this newsshared move
Travere Therapeutics to Submit sNDA for FILSPARI (sparsentan) in FSGS
Travere Therapeutics has announced its intention to submit a supplemental New Drug Application (sNDA) for FILSPARI, targeting focal segmental glomerulosclerosis (FSGS). The submission follows a successful Type C meeting with the FDA and will utilize data from the DUPLEX and DUET studies. If approved, FILSPARI could be the first treatment specifically indicated for FSGS, affecting over 40,000 patients in the U.S. However, while the studies demonstrated significant benefits, certain primary efficacy endpoints and safety risks must still be addressed.
Read more →TVTXTravere Therapeutics Provides Corporate Update and 2025 Outlook
Travere Therapeutics reported strong preliminary financial results for Q4 2024, with expected net product sales of approximately $74 million. The FDA has accepted a supplemental NDA for FILSPARI, targeting a decision by August 28, 2025. The company anticipates further regulatory updates regarding sparsentan for FSGS by its Q4 earnings call.
Read more →TVTXInvestors Media 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Provides Corporate Update and 2025 Outlook Received 693 new patient start forms for FILSPARI (sparsentan) i
Travere Therapeutics recently provided an update on its operations and expectations for 2025, highlighting significant developments for its product FILSPARI. The company reported receiving 693 new patient start forms and anticipates about $74 million in net product sales for the fourth quarter of 2024. Additionally, the FDA has accepted a supplemental New Drug Application for FILSPARI, which illustrates regulatory progress. The company expects ongoing commercial success while monitoring the impacts of their offering on patient health and safety, particularly regarding liver toxicity concerns.
Read more →TVTXTravere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Travere Therapeutics announced that CEO Eric Dube will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The presentation will be available via live webcast, with a replay accessible for 30 days. This event highlights the company's commitment to addressing rare diseases.
Read more →TVTXTravere Therapeutics to Present at Upcoming Investor Conferences
Travere Therapeutics, Inc. (NASDAQ: TVTX) announced its participation in two upcoming investor conferences in December 2024. The 7th Annual Evercore HealthCONx Conference is scheduled for December 3, followed by the Citi 2024 Global Healthcare Conference on December 4. Both events will be available via live webcast on the company's investor webpage, providing opportunities for broader engagement with potential investors.
Read more →TVTXTravere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
Travere Therapeutics, Inc. has successfully completed its public offering of 8,984,375 shares of common stock, priced at $16.00 per share. The offering included an exercise of the underwriters' option to purchase an additional 1,171,875 shares, bringing total gross proceeds to approximately $143.8 million. The shares were sold under a registration statement that became effective on August 1, 2024, and the company emphasized its commitment to developing therapies for rare diseases. Jefferies and Leerink Partners were the main managers for the offering.
Read more →TVTX▲ +12.4%on this newsshared move
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
Travere Therapeutics, Inc. has announced the pricing of a public offering involving 7,812,500 shares of common stock at $16.00 per share. This move is projected to generate gross proceeds of $125.0 million before costs. The offering is scheduled to conclude on November 12, 2024, pending customary closing conditions, and includes a 30-day option for underwriters to purchase additional shares. Jefferies and Leerink Partners serve as joint book-running managers for the offering.
Read more →TVTXTravere Therapeutics Announces Proposed Public Offering of Common Stock
Travere Therapeutics has announced plans for a proposed public offering of its common stock, which will be led by Jefferies and Leerink Partners. The offering includes a provision for underwriters to purchase an additional 15% of shares. However, the company has cautioned that completion of the offering is subject to market conditions and other uncertainties. The offering is made possible by a registration statement that was recently declared effective by the SEC.
Read more →TVTXInvestors Media 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Reports Third Quarter 2024 Financial Results FILSPARI (sparsentan) received full FDA approval as the only n
Travere Therapeutics announced its financial results for Q3 2024, highlighting the full FDA approval of FILSPARI for IgAN as a significant achievement. The approval positions FILSPARI as a leading non-immunosuppressive treatment that effectively slows kidney decline. The company reported strong revenue growth, with Q3 product sales reaching $61 million, despite a net loss of $54.8 million. Additionally, Travere is actively pursuing further indications for FILSPARI and expanding its commercial presence in Europe.
Read more →TVTXTravere Therapeutics Reports Third Quarter 2024 Financial Results
Travere Therapeutics reported a strong third quarter for 2024, highlighted by the full FDA approval of FILSPARI as the only non-immunosuppressive treatment for IgAN. The company noted significant growth in product sales, reaching $61 million, and an increase in demand following the expanded indication for FILSPARI. Additionally, a Type C meeting with the FDA has been scheduled to discuss a supplemental New Drug Application for the drug's use in FSGS. Despite these successes, Travere reported a net loss of $54.8 million for the quarter, contrasting with a profit in the same period the previous year.
Read more →TVTXTravere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
Travere Therapeutics presented significant new data on FILSPARI at ASN Kidney Week 2024, demonstrating its clinical benefits in treating IgA nephropathy (IgAN) and potential use in focal segmental glomerulosclerosis (FSGS). The SPARTAN Study showed nearly 60% of IgAN patients achieving complete remission, while the DUPLEX Study highlighted rapid proteinuria reduction in genetic FSGS cases. Additionally, combination therapy results indicated improved efficacy and safety, further validating FILSPARI's role in kidney health management. However, the treatment comes with a risk of hepatotoxicity, necessitating careful patient monitoring.
Read more →TVTXTravere Therapeutics to Report Third Quarter 2024 Financial Results
Travere Therapeutics, Inc. announced that it will report its financial results for the third quarter of 2024 on October 31, 2024. The announcement includes details of a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a business update. Following the live session, an archived version will be available for 30 days. This activity underscores the company's commitment to providing timely information to stakeholders.
Read more →TVTXTravere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy
Travere Therapeutics and CSL Vifor have announced that Swissmedic has granted temporary marketing authorization for FILSPARI, an oral treatment for adults with primary IgA nephropathy. The approval was supported by the Phase 3 PROTECT Study and follows previous authorizations by the FDA and EMA. FILSPARI aims to address a significant unmet medical need for targeted therapies in IgAN. However, it is associated with risks such as hepatotoxicity and requires a REMS program for distribution and patient management.
Read more →TVTX▲ +6.3%on this newsshared move
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
Travere Therapeutics announced it will present 11 abstracts, including a late-breaking study, at the ASN Kidney Week 2024. The presentations will focus on FILSPARI (sparsentan), detailing its efficacy and safety in treating IgA nephropathy as a first-line therapy, and will include data from various studies including SPARTAN, PROTECT, and DUPLEX. A key late-breaking presentation will examine sparsentan's effects on a high-risk subgroup with genetic focal segmental glomerulosclerosis. The company aims to reinforce the clinical benefits of sparsentan while emphasizing the need for careful safety monitoring.
Read more →TVTXJula Inrig Recognized in Endpoints News’ Women in Biopharma R&D, 2024
Jula Inrig, M.D., the chief medical officer at Travere, has been recognized in Endpoints News' 2024 Women Leaders in R&D. This annual recognition honors women who are making significant contributions and breaking boundaries in the field of Biopharma research and development.
Read more →TVTX▲ +15.6%on this newsshared move
William Rote Recognized in PharmaVoice 100 Industry Leaders Reshaping the Pharma World
William Rote, Ph.D., senior vice president of research and development at Travere, has been recognized in the PharmaVoice 100 list for his influential role in the life sciences sector. This list honors leaders who are driving change and innovation in the pharmaceutical industry. Rote's recognition underscores his significant contributions to the field.
Read more →TVTXTravere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
Travere Therapeutics has announced a voluntary pause in enrollment for its Phase 3 HARMONY Study evaluating the drug pegtibatinase for classical homocystinuria due to insufficient drug substance quality during a recent manufacturing scale-up. While currently enrolled patients will continue to receive their medication, the company aims to rectify the manufacturing issues before resuming enrollment, which is not expected to happen before 2026. The company remains optimistic about the drug's potential therapeutic benefits despite the challenges faced.
Read more →TVTXTravere CEO Eric Dube Named to Fortune’s LGBTQ+ Leaders List
Eric Dube, the president and CEO of Travere, has been named to Fortune's inaugural LGBTQ+ leaders list. This list honors 25 executives who have made significant contributions to their fields and paved the way for future leaders. Dube's recognition underscores the importance of diversity and inclusion in corporate leadership.
Read more →TVTXTravere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
Travere Therapeutics, Inc. has announced that its management will present at the 2024 Cantor Global Healthcare Conference on September 17, 2024. The presentation aims to share the company's efforts and commitment to developing treatments for rare diseases. Attendees will be able to access a live webcast via Travere's Investor page, with a replay available for 30 days post-event. This engagement emphasizes Travere's active role in the rare disease community.
Read more →TVTXTravere Therapeutics Announces Full FDA Approval of FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
Travere Therapeutics has achieved full FDA approval for FILSPARI (sparsentan) to treat adult patients with IgA nephropathy (IgAN) at risk of kidney function decline. The approval is based on results from the PROTECT Study, which demonstrated that FILSPARI offers significant benefits in preserving kidney function compared to irbesartan. This oral, non-immunosuppressive medication provides a new treatment option for those seeking effective management of IgAN, which is characterized by progressive kidney damage. Travere plans to enhance patient access through a support program and communication efforts regarding this milestone.
Read more →TVTXTravere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
Travere Therapeutics announced that it will present two posters at the upcoming Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Porto, Portugal, focusing on their investigational therapy pegtibatinase for classical homocystinuria. The presentations will include trial designs for the Phase 3 HARMONY Study and the Phase 1/2 COMPOSE Study. The company aims to demonstrate pegtibatinase's potential to replace the deficient CBS enzyme and hopes to position it as the first disease-modifying treatment for the disorder. The drug has already been granted multiple designations by the FDA, underscoring its significance in addressing this rare metabolic disease.
Read more →TVTXInvestors Media 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Reports Second Quarter 2024 Financial Results Received 521 new patient start forms (PSFs) for FILSPARI (spa
Travere Therapeutics reported its second quarter 2024 financial results, highlighting significant growth in patient start forms for FILSPARI, with 521 forms submitted. The company also noted a 37% increase in net product sales to $27.1 million. Preparations are underway for a crucial FDA decision on the full approval of FILSPARI in September 2024. However, the company reported a quarterly net loss of $70.4 million, despite growing revenues.
Read more →TVTXTravere Therapeutics Reports Second Quarter 2024 Financial Results
Travere Therapeutics announced its second quarter 2024 financial results, reporting substantial growth in both patient start forms and net product sales for its drug FILSPARI. The company received 521 new patient start forms, contributing to total net product sales of $27.1 million, marking a 37% growth over the previous quarter. Travere is preparing for a significant FDA decision on September 5, 2024, regarding the full approval of FILSPARI for IgAN. Despite the positive sales performance, the company reported a significant net loss of $70.4 million in the second quarter.
Read more →TVTXTravere Therapeutics to Report Second Quarter 2024 Financial Results
Travere Therapeutics, Inc. (NASDAQ: TVTX) has announced that it will release its financial results for the second quarter of 2024 on August 1, 2024, following the closing of U.S. financial markets. A conference call and webcast is scheduled for the same day at 4:30 p.m. ET, where the company will discuss its results and provide a business update. Those interested can access the call via the company's Investor page, and an archived version will be available for 30 days post-event.
Read more →TVTX▲ +10.5%on this news· ran to +24% by day 3
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Travere Therapeutics, a biopharmaceutical company focused on rare diseases, will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on July 15, 2024, at 11:30 a.m. ET. The presentation will be accessible via a live webcast on Travere's investor relations webpage, with a replay available for 30 days after the event. This participation underscores Travere's ongoing commitment to addressing urgent treatment needs in the rare disease community.
Read more →TVTXEndpoints News Names Eric Dube a 2024 LGBTQ+ Leader in BioPharma
Eric Dube, Ph.D., president and CEO of Travere, has been recognized as an LGBTQ+ Leader in Biopharma by Endpoints News. In his interview, he discusses the influence of past activists during the AIDS and HIV epidemic on current patient advocacy and drug development. Dube emphasizes the significance of health equity and understanding patient needs.
Read more →TVTXTravere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
Travere Therapeutics will present nine abstracts on FILSPARI (sparsentan) at the upcoming National Kidney Foundation Spring Clinical Meetings and European Renal Association Congress. Key findings from the Phase 3 PROTECT Study and new data from the SPARTAN Study will highlight FILSPARI's effectiveness compared to RAS inhibition in patients with IgA nephropathy. This presentation aims to establish FILSPARI as a first-line treatment and a foundational therapy for managing these rare kidney conditions.
Read more →TVTXTravere Therapeutics Reports First Quarter 2024 Financial Results
Travere Therapeutics reported strong financial results for Q1 2024, highlighting notable growth in the demand for its kidney disease treatment, FILSPARI. The FDA has granted a Priority Review for converting FILSPARI's accelerated approval into a full approval, with a target action date set for September 5, 2024. The company also announced a conditional marketing authorization for FILSPARI in Europe, with first launches expected in the second half of 2024. However, Travere reported a net loss of $136.1 million for the quarter, reflecting ongoing expenses related to research and development and strategic restructuring.
Read more →TVTXInvestors Media 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Reports First Quarter 2024 Financial Results FDA grants Priority Review for sNDA to convert FILSPARI (spars
Travere Therapeutics reported its first quarter 2024 financial results, highlighting a strong demand for its product FILSPARI, which has garnered FDA's Priority Review for full approval. The company achieved net product sales of $19.8 million and received attention for its recent conditional marketing authorization for FILSPARI in Europe. Despite these gains, Travere reported a net loss of $136.1 million for the quarter.
Read more →TVTXTravere Therapeutics to Report First Quarter 2024 Financial Results
Travere Therapeutics, Inc. will announce its first quarter 2024 financial results on May 6, 2024, following the close of U.S. markets. A conference call and webcast are scheduled for 4:30 p.m. ET to discuss the results and provide a general business update. The webcast will be accessible through the company's investor page and will remain archived for 30 days after the event.
Read more →TVTX▼ -5.1%on this newsshared move
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy
Travere Therapeutics and CSL Vifor announced that the European Commission has granted conditional marketing authorization for FILSPARI (sparsentan) to treat adults with primary IgA nephropathy (IgAN). This approval, which is based on significant results from the Phase 3 PROTECT Study, makes FILSPARI the first non-immunosuppressive therapy available for IgAN. Patients in Europe will have access to this innovative treatment, which has been shown to significantly reduce proteinuria and slow the progression of kidney disease. However, the approval is conditional on further verification of the drug's clinical benefits.
Read more →TVTXTravere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Travere Therapeutics announced it will present eight posters at two prominent medical meetings in April 2024, highlighting their work on classical homocystinuria (HCU). Key topics will include the pivotal Phase 3 HARMONY Study of pegtibatinase, an investigational treatment aimed at addressing HCU. The presentations will showcase trial designs and innovative dietary management tools, as well as positive results from previous studies. This effort underscores the company's role in pioneering treatment options for this rare genetic disorder.
Read more →TVTXTravere Therapeutics to Present Abstracts on FILSPARI (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Travere Therapeutics will showcase nine abstracts related to its drug FILSPARI at two upcoming conferences in April 2024. Presentations will include subgroup analyses from the Phase 3 PROTECT Study and insights from the HONUS trial. The data supports FILSPARI's potential role as a foundational treatment for IgA nephropathy, with an aim to improve patient outcomes and address quality of life concerns. The presentations will provide further evidence on the treatment's effectiveness and patient management strategies.
Read more →TVTXTravere Therapeutics Named a Finalist for the Citeline Awards Excellence in Rare Disease Drug Development
Travere Therapeutics has been named a finalist for the Citeline Awards 2024 in the category of Excellence in Rare Disease Drug Development. This recognition is for their work in classical homocystinuria, showcasing their innovative Phase 3 HARMONY Study design and ongoing efforts to modernize newborn screening. The award highlights the importance of patient-centric processes in rare disease drug development.
Read more →TVTX▼ -7.7%on this newsshared move
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA, seeking full approval of FILSPARI (sparsentan) for IgA nephropathy treatment. This submission is underpinned by promising results from the Phase 3 PROTECT Study, which demonstrated FILSPARI's effectiveness in reducing proteinuria. If approved, FILSPARI would offer a critical non-immunosuppressive treatment option for patients with this rare kidney disease. The FDA is expected to provide feedback on the sNDA within 60 days, while the EMA has already recommended conditional marketing authorization in Europe.
Read more →TVTXTravere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
Travere Therapeutics and CSL Vifor announced that the CHMP has recommended conditional marketing authorization for sparsentan, aimed at treating IgA nephropathy in adults. This positive opinion is contingent on the Phase 3 PROTECT Study results, which indicate sparsentan's potential to significantly reduce proteinuria and improve kidney function. The final decision from the European Commission is expected in the second quarter of 2024, representing a crucial step towards providing new treatment options for this rare kidney disease.
Read more →TVTX▲ +5.9%on this news
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Travere Therapeutics reported a strong performance in Q4 2023, with net product sales of $39.9 million and anticipation of a supplemental New Drug Application for FILSPARI to achieve full approval in the U.S. The company also expects a positive opinion from the CHMP for the treatment of IgAN in Europe and is actively enrolling patients in its pivotal Phase 3 HARMONY Study for pegtibatinase in classical homocystinuria. Despite a notable net loss for the quarter, Travere's financial position remains robust with $566.9 million in cash and equivalents as of December 31, 2023.
Read more →TVTX▲ +5.9%on this news
Investors Media 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Received 459 new patient start forms (PSFs) for
Travere Therapeutics reported its financial results for Q4 and FY 2023, showing significant progress with 459 new patient start forms for FILSPARI during Q4. The company is preparing to submit a supplemental New Drug Application for FILSPARI, aiming to convert U.S. accelerated approval to full approval. Additionally, a CHMP opinion on potential sparsentan approval in Europe is anticipated in early 2024, while a pivotal Phase 3 study for pegtibatinase in classical homocystinuria has commenced. Despite growth in sales, the company reported an increased net loss due to higher R&D and administrative expenses.
Read more →TVTXTravere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
Travere Therapeutics, Inc. has announced its participation in the Guggenheim 6th Annual Biotechnology Conference scheduled for February 8, 2024. The presentation will take place at 11:30 a.m. ET and will be accessible via a live webcast on the company's investor website. A replay of the event will also be available for 30 days, allowing more stakeholders to engage with the company's efforts in rare disease therapies.
Read more →TVTXTravere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
Travere Therapeutics has entered an exclusive licensing agreement with Renalys Pharma to develop and commercialize sparsentan in Japan and several Southeast Asian nations. This partnership will allow Renalys to initiate a registrational study for sparsentan in Japan, with expected results in 2025 to support regulatory approval. Travere will receive an upfront payment and may earn up to $120 million in milestone payments, along with royalties on net sales. The agreement aims to provide new treatment options for patients suffering from IgA nephropathy in the region.
Read more →TVTX▲ +13.7%on this news
Travere Therapeutics Provides Corporate Update and 2024 Outlook
Travere Therapeutics provided a corporate update highlighting strong preliminary financial results, including expected net product sales of approximately $40 million for Q4 2023. The company received 459 new patient start forms for its product FILSPARI, which is positioned for potential full FDA approval in 2024. Additionally, the firm has initiated the Phase 3 HARMONY Study for pegtibatinase, aiming to establish it as the first disease-modifying therapy for classical homocystinuria. The company maintains a solid cash position of around $567 million, which is expected to support its operations into 2028.
Read more →TVTX▲ +13.7%on this news
Investors: Media: 888-969-7879 888-969-7879 ir@travere.com mediarelations@travere.com Travere Therapeutics Provides Corporate Update and 2024 Outlook Received 459 new patient start forms for FILSPARI (sparsentan
Travere Therapeutics provided a corporate update highlighting strong Q4 2023 performance with anticipated net sales of approximately $40 million and 459 new patient start forms for FILSPARI, indicating positive momentum. The company is preparing to submit a supplemental NDA to the FDA for full approval of FILSPARI in IgAN and expects a decision on potential European approval in early 2024. Additionally, the pivotal HARMONY Study for pegtibatinase has begun, aiming to position it as the first disease-modifying therapy for classical homocystinuria. Despite positive developments, preliminary results are unaudited, and the company must navigate the risks associated with FILSPARI's side effects.
Read more →TVTX▲ +6.3%on this news
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Travere Therapeutics, Inc. announced that its CEO, Eric Dube, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The conference is known for highlighting key developments in the healthcare sector. A live webcast of the presentation will be available on Travere's investor website, with a replay accessible for 30 days afterward. This event represents an opportunity for the company to showcase its commitment to developing life-changing therapies for rare diseases.
Read more →TVTXTravere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
Travere Therapeutics has commenced enrollment in the HARMONY Study, a pivotal Phase 3 clinical trial for pegtibatinase, targeted at treating classical homocystinuria (HCU). This investigational enzyme replacement therapy seeks to lower plasma total homocysteine levels in patients diagnosed with HCU, a rare genetic disorder with limited treatment options. The study will compare the efficacy of pegtibatinase against a placebo and aims to determine the therapy's safety and effectiveness. Positive results from previous studies support its advancement to this stage.
Read more →TVTXTravere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
Travere Therapeutics has completed a successful pre-NDA meeting with the FDA for its drug FILSPARI in IgA nephropathy (IgAN) and plans to submit a supplemental New Drug Application (sNDA) for full approval in Q1 2024. While the FDA acknowledged the high unmet need for therapies in focal segmental glomerulosclerosis (FSGS), they found insufficient data from the Phase 3 DUPLEX Study to support an sNDA submission, prompting further analyses. In light of these developments, the company is reorganizing to prioritize its FILSPARI launch and plans to reduce its workforce to extend its cash runway into 2028.
Read more →TVTXTravere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
Travere Therapeutics, Inc. has announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on November 28, 2023. The presentation will be available via a live webcast, and a replay will be offered for 30 days post-event. This engagement underscores Travere's commitment to addressing rare diseases and connecting with the healthcare community.
Read more →TVTXBiotech Breakthrough Awards Travere Therapeutics Overall Biopharma Company of the Year
Travere Therapeutics has been awarded the title of Overall Biopharma Company of the Year by the 2023 Biotech Breakthrough Awards. This recognition is based on the company's innovative contributions to the biotech field. The awards celebrate companies that have made significant advancements in biotechnology.
Read more →TVTX▲ +8.1%on this news
Travere Therapeutics Reports Third Quarter 2023 Financial Results
Travere Therapeutics reported strong third quarter results for 2023, showcasing substantial growth in FILSPARI patient starts and increased net product sales, totaling $33.9 million compared to $25.4 million in Q3 2022. The company successfully completed critical clinical studies for FILSPARI and presented positive long-term outcomes at the ASN Kidney Week, further solidifying its potential as a standard treatment for IgA nephropathy. The company also benefited from a significant sale of its bile acid product portfolio, bolstering its financial position with $634.6 million in cash and equivalents as of the end of September.
Read more →TVTX▲ +8.1%on this news
Investors Media Naomi Eichenbaum Nivi Nehra Vice President, Investor Relations Vice President, Corporate Communications 888-969-7879 888-969-7879 IR travere.com mediarelations travere.com Travere Therapeutics Rep
Travere Therapeutics reported its Q3 2023 financial results, highlighting net product sales of $33.9 million, up from $25.4 million in the same period last year. The company continues to focus on expanding the launch of FILSPARI, which has received positive responses from both patients and payers. Recent Phase 3 study results indicate that FILSPARI may provide significant renal benefits for those with IgA nephropathy, and the company anticipates further updates on its regulatory submissions in the coming quarter. Overall, the financial position of Travere appears robust, supported by a recent portfolio sale for up to $445 million.
Read more →TVTX▲ +5.9%on this newsshared move
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
Travere Therapeutics announced positive data from two pivotal Phase 3 studies, PROTECT and DUPLEX, regarding sparsentan's efficacy in patients with IgAN and FSGS. The results suggest that sparsentan can significantly delay kidney failure and preserve kidney function over two years, outperforming the active comparator irbesartan. The findings were shared at the American Society of Nephrology Kidney Week 2023 and published in prestigious journals. Both studies demonstrated sparsentan's durability and safety profile, indicating its potential as a substantial treatment option in the nephrology field.
Read more →TVTXTravere Therapeutics to Report Third Quarter 2023 Financial Results
Travere Therapeutics, Inc. has announced that it will report its financial results for the third quarter of 2023 on November 7, 2023, after U.S. market close. In conjunction with the financial report, the company will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update. Investors can access the webcast on the company's investor page, where an archived version will also be available for 30 days afterward.
Read more →TVTXTravere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
Travere Therapeutics plans to present 11 abstracts at the American Society of Nephrology Kidney Week 2023, including two late-breaking oral sessions. The presentations will focus on the long-term efficacy and tolerability of FILSPARI (sparsentan) for IgA nephropathy (IgAN) from the PROTECT Study, and its use as a first-line treatment. Data regarding sparsentan's effectiveness in focal segmental glomerulosclerosis (FSGS) and pediatric patients will also be shared, demonstrating Travere's leadership in rare kidney disease research.
Read more →TVTX▲ +6%on this news
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
Travere Therapeutics will present preliminary findings from the SPARTAN Study on FILSPARI, focusing on its potential as a first-line therapy for IgA nephropathy, at the 17th International Symposium on IgA Nephropathy in Tokyo. The presentations will cover interim data on proteinuria reduction and an analysis revealing high kidney failure rates in traditionally low-risk IgAN patients. Despite its promise, FILSPARI carries significant safety warnings, including risks of hepatotoxicity and potential birth defects.
Read more →TVTX▼ -40.7%on this newsshared move
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
Travere Therapeutics announced confirmatory results from its pivotal Phase 3 PROTECT Study, showing that FILSPARI (sparsentan) achieved long-term kidney function preservation in patients with IgA nephropathy. While it demonstrated statistical significance in eGFR chronic slope, it narrowly missed the eGFR total slope endpoint. All efficacy endpoints favored FILSPARI over the active control, irbesartan. The company plans to engage with regulators and expects to submit a supplemental New Drug Application for full approval in the first half of 2024.
Read more →TVTXStevie Awards Recognize Travere Therapeutics as a Great Employer
Travere Therapeutics has been honored with a bronze award by The Stevie Awards for Great Employers. This recognition underscores the company's efforts in creating a positive work environment. The Stevie Awards acknowledge outstanding employers worldwide, and Travere's achievement reflects its commitment to employee satisfaction.
Read more →TVTXTravere Therapeutics Joins American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ Level
Travere Therapeutics has become a Champion-level member of the American Kidney Fund's 2023 Corporate Membership Program. This partnership will help fund AKF’s initiatives focused on kidney disease awareness, prevention, and treatment. Travere has previously collaborated with AKF on several fronts, including supporting the Patient Access Initiative and community outreach programs. Their membership aims to address barriers faced by kidney disease patients and promote health equity, especially regarding rare kidney conditions.
Read more →TVTXTravere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
Travere Therapeutics has successfully completed the sale of its bile acid product portfolio, which includes Cholbam and Chenodal, to Mirum Pharmaceuticals. The deal provided Travere with an upfront payment of $210 million and potential additional earnings of up to $235 million through sales-based milestones. This transaction is seen as a strategic move to enhance Travere's financial stability and focus on developing treatments for rare diseases, while Mirum strengthens its market presence in rare liver diseases with the acquisition of these products.
Read more →TVTX▲ +8.3%on this newsshared move
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
Travere Therapeutics has announced its participation in the 2023 Wells Fargo Healthcare Conference, scheduled for September 7, 2023. The company's management will present at 10:15 a.m. ET, with a live webcast available on their investor relations page. Following the event, a replay will be accessible for up to 30 days, reflecting Travere's commitment to stakeholder engagement.
Read more →TVTXTravere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
Travere Therapeutics will present clinical findings related to its investigational enzyme replacement therapy, pegtibatinase, at the upcoming SSIEM Annual Symposium in Jerusalem. The data includes results from the Phase 1/2 COMPOSE Study and insights into the burden of classical homocystinuria, a rare genetic disorder. Notably, the research has been highlighted for its significance, indicating the urgent need for new treatment avenues in this area.
Read more →TVTXTravere Therapeutics Reports Second Quarter 2023 Financial Results
Travere Therapeutics reported its second quarter 2023 financial results, showing strong early demand for its product FILSPARI, which received 417 new patient start forms. The company achieved net product sales of $3.5 million for FILSPARI during the quarter, with total revenues reaching $59.7 million. However, it also reported a net loss of $85.6 million, which was higher than the previous year's loss. The company announced plans to sell its bile acid product portfolio, a move expected to bolster its financial position and focus on its drug pipeline, including a potential pivotal study for pegtibatinase.
Read more →TVTXTravere Therapeutics to Report Second Quarter 2023 Financial Results
Travere Therapeutics, Inc. has announced that it will report its second quarter 2023 financial results on August 3, 2023, after market close. The company will also conduct a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a general business update. The event can be accessed through the Investor page of the Travere website, and an archived version of the call will be available for 30 days.
Read more →TVTXEric Dube Named a CEO of the Year by San Diego Business Journal
Eric Dube, Ph.D., has been named CEO of the Year by the San Diego Business Journal for his leadership at Travere Therapeutics. His recognition highlights his commitment to business growth and innovation in the biotech sector, particularly in developing treatments for rare diseases. Dube emphasizes the importance of teamwork and vision in his role.
Read more →TVTXTravere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
Travere Therapeutics has entered into a definitive agreement to sell its bile acid product portfolio, including Cholbam® and Chenodal®, to Mirum Pharmaceuticals for up to $445 million. The agreement consists of $210 million upfront and potential milestone payments based on sales performance. This strategic divestment will enable Travere to invest resources into the development of its ongoing treatments for rare diseases. The transaction is expected to close in the third quarter of 2023, subject to regulatory approval.
Read more →TVTX▼ -7.4%on this news
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
Travere Therapeutics announced that it will present nine abstracts at the upcoming 60th European Renal Association Congress in Milan, Italy. These presentations will include interim results from the Phase 3 PROTECT Study of FILSPARI in IgA nephropathy, which are showing promising findings related to proteinuria reduction. Additionally, one of the analyses will address the timely progression to kidney failure based on a registry study, earning a spot among the 10 best-ranked abstracts of the conference. The presentations are scheduled for June 15-18, 2023.
Read more →TVTX▲ +9%on this newsshared move
Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
Travere Therapeutics announced positive topline results from cohort 6 of the Phase 1/2 COMPOSE study for pegtibatinase, showcasing a significant 67.1% mean reduction in total homocysteine levels in patients. The treatment has been well-tolerated, with no severe adverse events recorded. Moving forward, the company is engaging with regulators and aims to initiate a pivotal Phase 3 study by the end of 2023. These findings continue to indicate the potential of pegtibatinase as a disease-modifying therapy for classical homocystinuria.
Read more →TVTXTravere Therapeutics Reports First Quarter 2023 Financial Results
FILSPARI™(sparsentan) granted accelerated approval by FDA for the reduction of proteinuria in IgA nephropathy (IgAN) on February 17th, 2023; commercial launch underway Total net product sales of $50.3 million for the first quarter of 2023, including $3.0 million for FILSPARI SA
Read more →TVTXTravere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 wee
Read more →TVTXTravere Therapeutics to Report First Quarter 2023 Financial Results
SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast
Read more →TVTXTravere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) in adults with I
Read more →TVTXTravere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) in IgA nephropathy (IgAN) will be presented in la
Read more →TVTXTravere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present a quantitative systems pharmacology (QSP) model for predicting the effects of the investigational enzyme replacement therapy pegtibatinase, in cla
Read more →TVTXTravere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 9,703,750 shares of its common stock at a price to the public of $21.00 per share and pre-funded warr
Read more →TVTXTravere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 8,275,000 shares of its common stock at a price to the public of $21.00 per share and, in lieu of common stock to investors who
Read more →TVTXTravere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Recently received U.S. FDA accelerated approval of FILSPARI™ (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy (IgAN) European Medicines Agency (EMA) review decision for potential conditional approval of sparsentan
Read more →TVTX▼ -12.2%on this newsshared move
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients with IgA nephropathy (IgAN) Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a rapid, sustained and clinically meaningful reduction in prot
Read more →TVTXTravere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after the close of the U.S. financial markets. Management will provide an upda
Read more →TVTXNaomi Eichenbaum Vice President, Investor Relations IR@travere.com 888-969-7879 Travere Therapeutics Provides Corporate Update and 2023 Outlook Company well-positioned for potential FDA Subpart H approval and co
Travere Therapeutics has provided a corporate update and outlook for 2023, highlighting the potential FDA approval for sparsentan, a treatment for IgA nephropathy, expected in the first quarter. The company anticipates net sales of approximately $212 million for 2022. Furthermore, Travere plans to initiate a Phase 3 program for pegtibatinase, which aims to be a disease-modifying therapy for classical homocystinuria. The upcoming year is deemed pivotal with several anticipated regulatory milestones.
Read more →TVTXTravere Therapeutics Provides Corporate Update and 2023 Outlook
Company well-positioned for potential FDA Subpart H approval and commercial launch of sparsentan for IgA nephropathy (IgAN) in 1Q23, followed by potential EMA approval in second half of 2023 Preliminary net product sales of $201 million for the full year 2022 SAN DIEGO, Jan. 09
Read more →TVTXTravere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference, on Thursday, January 12, 20
Read more →TVTXTravere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease. SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., the IgA Nephropathy Foundation, and NephCure Kidney Int
Read more →TVTXTravere Therapeutics Reports Third Quarter 2022 Financial Results
EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for sparsentan in IgAN set for February 17, 2023 Net product sales of $50.8 million for th
Read more →TVTXTravere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present data from its sparsentan programs, including long-term clinical data from the ongoing Phase 2 DUET Study in focal segmental g
Read more →TVTXTravere Therapeutics to Report Third Quarter 2022 Financial Results
SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2022 financial results on Thursday, October 27, 2022, after the close of the U.S. financial markets. The Company will host a conference call and web
Read more →TVTXTravere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
Conference call and webcast to be held at 4:30p.m. ET SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the pr
Read more →TVTXTravere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of cognitive function from the Company’s ongoing longitudinal natural history study of p
Read more →TVTXTravere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy
A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical need in IgA nephropathy (IgAN) in Europe SAN DIEGO and ST. GALLEN, Switzerland, Au
Read more →TVTX▲ +7.5%on this news
Chris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 IR@travere.com Travere Therapeutics Reports Second Quarter 2022 Financial Results
Senior Vice President, Investor Relations & Corporate Communications Travere Therapeutics Reports Second Quarter 2022 Financial Results SAN DIEGO, August 4, 2022 Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a
Read more →TVTX▲ +7.5%on this news
Travere Therapeutics Reports Second Quarter 2022 Financial Results
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update. New Drug Application (NDA) for accelerated approval of sparsentan in IgA nephropathy (IgAN) accepted b
Read more →TVTXTravere Therapeutics Provides Regulatory Updates on its Development Programs
PDUFA target action date for NDA for sparsentan in IgAN on-track for November 17, 2022 Company to utilize traditional approval process for sparsentan in FSGS following completion of the pivotal Phase 3 DUPLEX Study in 2023 Company and its partner Vifor Pharma applying for condi
Read more →TVTXTravere Therapeutics to Report Second Quarter 2022 Financial Results
SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webca
Read more →TVTXTravere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET. A live webcast will be available at https://ir.trav
Read more →TVTX▲ +9.1%on this news
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy (IgAN) and focal
Read more →TVTX▲ +6.1%on this newsshared move
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for
Read more →TVTX▼ -5.1%on this news
Chris Cline, CFA Senior Vice President, Investor Relations Corporate Communications 888-969-7879 IR travere.com Travere Therapeutics Reports First Quarter 2022 Financial Results Submitted New Drug Application (ND
Contact Chris Cline, CFA Senior Vice President, Investor Relations Corporate Communications 888-969-7879 IR travere.com Travere Therapeutics Reports First Quarter 2022 Financial Results Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Result
Read more →TVTX▼ -5.1%on this news
Travere Therapeutics Reports First Quarter 2022 Financial Results
Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society for Inherited Metabolic Disorders (SIMD) 43rd Annual Meeting Refinanced $207 mil
Read more →TVTXTravere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 4:00 p.m. PT. A live we
Read more →TVTXTravere Therapeutics to Report First Quarter 2022 Financial Results
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of the U.S. financial markets. The Company will host a conference call and webcast
Read more →TVTXTravere Therapeutics Announces Plan for Chief Financial Officer Transition
Laura Clague to step-down as CFO in August 2022 and retire in 2023 Chris Cline, Travere SVP of Investor Relations & Corporate Communications, to assume position of chief financial officer in August 2022 SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (N
Read more →TVTXTravere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatme
Read more →TVTXTravere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the treatment of Ig
Read more →TVTX▲ +6.4%on this newsshared move
Travere Prices Upsized $275 Million Convertible Senior Notes Offering
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $275 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the “Notes”). The sale of the Notes is expected
Read more →TVTX▼ -11.5%on this newsshared move
Travere Announces Proposed Convertible Senior Notes Offering
Travere Announces Proposed Convertible Senior Notes Offering SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertib
Read more →TVTXTravere Therapeutics to Present at the Barclays Global Healthcare Conference
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2022 at 8:30 a.m. ET. A live webcast will be available at https://ir.t
Read more →TVTXTravere Therapeutics Recognizes Rare Disease Day 2022 and Raises Awareness for People Living with Rare Disease
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), and the rare community worldwide in recognizing today as Rare Disease Day 2022
Read more →TVTXTravere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022 Company positioned for potential NDA submission for accelerated approval of sparsentan in FSGS and combined IgA nephropathy and FSGS MAA submission mid-year 2022 Recently reported positive topline r
Read more →TVTXChris Cline, CFA Senior Vice President, Investor Relations Corporate Communications 888-969-7879 IR travere.com Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results NDA submission of s
Contact Chris Cline, CFA Senior Vice President, Investor Relations Corporate Communications 888-969-7879 IR travere.com Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results NDA submission of sparsentan in IgA nephropathy on-track for first quarter 20
Read more →TVTXTravere Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022 after the close of the U.S. financial markets. The Company will host a conferen
Read more →TVTXTravere Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 2:20 p.m. ET.
Read more →TVTXChris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 IR@travere.com Travere Therapeutics Provides Corporate Update and 2022 Outlook Company positioned for multiple N
Senior Vice President, Investor Relations & Corporate Communications Travere Therapeutics Provides Corporate Update and 2022 Outlook Company positioned for multiple NDA and MAA submissions for accelerated approval in 2022 SAN DIEGO, January 10, 2022 Travere Therapeutics (NASD
Read more →TVTXTravere Therapeutics Provides Corporate Update and 2022 Outlook
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2021 to be approximately $55 million. For the fiscal year 2021
Read more →TVTXTravere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug deve
Read more →TVTX▲ +10.6%on this news
Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
Treatment with highest dose pegtibatinase led to a clinically meaningful 55% mean reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment Results provide clinical proof of concept for first potential therapy targeting the underl
Read more →TVTXTravere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data describing the potential for sparsentan, an investigational product candidate, to protec
Read more →TVTXTravere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress
Recently reported positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan in IgA nephropathy Following pre-NDA interactions with FDA, NDA submission of sparsentan in IgA nephropathy for accelerated approval under Subpart H expected in the fi
Read more →TVTXChris Cline, CFA Senior Vice President, Investor Relations Corporate Communications 888-969-7879 IR travere.com Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress Recent
Contact Chris Cline, CFA Senior Vice President, Investor Relations Corporate Communications 888-969-7879 IR travere.com Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress Recently reported positive topline interim results from the ongo
Read more →TVTXTravere Therapeutics to Report Third Quarter 2021 Financial Results
SAN DIEGO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2021 financial results on Thursday, October 28, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webc
Read more →TVTXTravere Therapeutics Announces Transition of Chief Medical Officer
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief medical officer, Noah Rosenberg, M.D., has chosen to transition for personal reasons to an executive advisor role at the end of 2021. Dr. Rosenberg is expected to
Read more →TVTXTravere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand
Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand Travere receives a $55 million upfront payment and is eligible for additional regulatory and commercial milestones, as well as tiered royalties on net sales Sparsentan is
Read more →TVTXTravere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors
SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company’s Board of Directors, effective immediately. Ms. Williams-Brinkley brings to Travere more than 35 years of executive le
Read more →TVTX▲ +7.1%on this news
Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug Administration (FDA) in which alignment was reached on the Company’s plan to submit additiona
Read more →TVTX▲ +15.3%on this news
Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Sparsentan treatment group experienced 49.8 percent mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator; interim primary efficacy endpoint achieved, p<0.0001 To date in the study, sparsentan has been generally well-t
Read more →TVTXChris Cline, CFA Senior Vice President, Investor Relations Corporate Communications 888-969-7879 IR travere.com Travere Therapeutics Reports Second Quarter 2021 Financial Results Company expects to submit an appl
Contact Chris Cline, CFA Senior Vice President, Investor Relations Corporate Communications 888-969-7879 IR travere.com Travere Therapeutics Reports Second Quarter 2021 Financial Results Company expects to submit an application for conditional marketing authorization of sparsen
Read more →TVTXTravere Therapeutics Reports Second Quarter 2021 Financial Results
Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 Pivotal PROTECT Study of sparsentan in IgA nephropathy on track to report topline data from interim 36-week proteinuria endpoint in August 2021
Read more →TVTX▼ -5.5%on this news
Travere Therapeutics to Report Second Quarter 2021 Financial Results
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcas
Read more →TVTXTravere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high affinity antagonist of both endothelin type A (ETA) and angiotensin II type 1 (AT
Read more →TVTXTravere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy
Read more →TVTXTravere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS). Following achievement of the interim proteinuria endpoint in the ongoing Phase 3 DUPLE
Read more →TVTXChris Cline, CFA Senior Vice President, Investor Relations Corporate Communications 888-969-7879 IR travere.com Travere Therapeutics Reports First Quarter 2021 Financial Results Pivotal PROTECT Study of sparsenta
Contact Chris Cline, CFA Senior Vice President, Investor Relations Corporate Communications 888-969-7879 IR travere.com Travere Therapeutics Reports First Quarter 2021 Financial Results Pivotal PROTECT Study of sparsentan in IgA nephropathy nears completion of patient enrollmen
Read more →TVTXTravere Therapeutics Reports First Quarter 2021 Financial Results
Pivotal PROTECT Study of sparsentan in IgA nephropathy nears completion of patient enrollment; topline proteinuria data expected 3Q21 Net product sales of $47.4 million for the first quarter of 2021 SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:
Read more →TVTXTravere Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 5:00 p.m. ET. A live webcas
Read more →TVTXTravere Therapeutics to Report First Quarter 2021 Financial Results
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast
Read more →TVTXTravere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
Recently reported that ongoing DUPLEX Study of sparsentan in FSGS achieved interim proteinuria endpoint Preparations underway for meetings with regulatory agencies in first half of 2021 to discuss planned accelerated approval submissions for FSGS Pivotal PROTECT Study of sparse
Read more →TVTXTravere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), EveryLife Foundation for Rare Diseases, Global Genes, and rare disease adv
Read more →TVTXTravere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage ki
Read more →TVTXTravere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results
SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2020 financial results on Monday, March 1, 2021 after the close of the U.S. financial markets. The Company will host a conference cal
Read more →TVTXChris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 IR@travere.com Travere Therapeutics Announces Proposed Public Offering of Common Stock
Senior Vice President, Investor Relations & Corporate Communications Travere Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO, February 10, 2021 Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underw
Read more →TVTXTravere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment To date in the study, sparsentan has been generally well-tolerated and has shown a safety profile comparable to irbesartan Company to host c
Read more →TVTXTravere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a lead
Read more →TVTXChris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 IR@travere.com Travere Therapeutics Provides Corporate Update and 2021 Outlook Pipeline of potential first-in-cl
Contact: Chris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 IR@travere.com Travere Therapeutics Provides Corporate Update and 2021 Outlook Pipeline of potential first-in-class therapies on track to deliver two pivotal readouts in
Read more →TVTXTravere Therapeutics Provides Corporate Update and 2021 Outlook
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2020 to be approximately $51 million. For the fiscal year 2020
Read more →TVTXTravere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that the Company will host a virtual R&D Day on Wednesday, December 9, 2020 at 12:00 p.m. ET to review the Company’s key pipeline programs. The event will feature presentations from e
Read more →TVTXTravere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomeru
Read more →TVTXChris Cline, CFA Senior Vice President, Investor Relations Corporate Communications 888-969-7879 IR retrophin.com Retrophin Reports Third Quarter 2020 Financial Results Pivotal DUPLEX Study of sparsentan in FSGS
Contact Chris Cline, CFA Senior Vice President, Investor Relations Corporate Communications 888-969-7879 IR retrophin.com Retrophin Reports Third Quarter 2020 Financial Results Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment topline proteinuria data ex
Read more →TVTXChris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications Retrophin, Inc. 888-969-7879 IR@retrophin.com Retrophin Announces Proposed Public Offering of Common Stock
Senior Vice President, Investor Relations & Corporate Communications Retrophin Announces Proposed Public Offering of Common Stock SAN DIEGO, June 8, 2020 Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwrit
Read more →TVTXChris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 IR@retrophin.com Retrophin Provides Corporate Update and 2020 Outlook SAN DIEGO (
Senior Vice President, Investor Relations & Corporate Communications Corporate Update and 2020 Outlook SAN DIEGO (January 13, 2020) - Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales f
Read more →TVTXRetrophin, Inc. 2018 Equity Incentive Plan Adopted by the Board of Directors
2018 Equity Incentive Plan Adopted by the Board of Directors: April 1, 2018 Approved by the Stockholders: May 9, 2018 Amended by the Board of Directors: April 1, 2019 Approved by the Stockholders: May 8, 2019 (a)Successor to and Continuation of Prior Plans. The Plan is inten
Read more →TVTXChris Cline, CFA Vice President, Investor Relations & Corporate Communications 760-260-8600 IR@retrophin.com Retrophin Provides Corporate Update and 2019 Outlook Top-line readout of pivotal FORT Study in PKAN ex
Vice President, Investor Relations & Corporate Communications Retrophin Provides Corporate Update and 2019 Outlook Top-line readout of pivotal FORT Study in PKAN expected 3Q19 SAN DIEGO (January 7, 2019) - Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on prelimin
Read more →TVTXChris Cline, CFA Vice President, Investor Relations & Corporate Communications 760-260-8600 IR@retrophin.com Retrophin Names Eric Dube, Ph.D. President and Chief Executive Officer Dr. Dube brings proven track re
Vice President, Investor Relations & Corporate Communications Retrophin Names Eric Dube, Ph.D. President and Chief Executive Officer Dr. Dube brings proven track record of global leadership built upon significant commercial and operational success Dr. Dube succeeds Stephen Ase
Read more →TVTXRetrophin Announces Proposed Convertible Senior Notes Offering
Retrophin Announces Proposed Convertible Senior Notes Offering SAN DIEGO, Sept. 04, 2018 (GLOBE NEWSWIRE) Retrophin, Inc. (NASDAQ: RTRX) today announced its intention to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior
Read more →TVTXChris Cline, CFA Vice President, Investor Relations & Corporate Communications 760-260-8600 IR@retrophin.com Retrophin Provides Corporate Update and 2018 Outlook Preliminary full-year 2017 revenue of approximate
Vice President, Investor Relations & Corporate Communications Retrophin Provides Corporate Update and Preliminary full-year 2017 revenue of approximately $155 million SAN DIEGO (January 8, 2018) Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unau
Read more →TVTXRetrophin, Inc. 2015 Equity Incentive Plan Adopted by the Board of Directors
2015 Equity Incentive Plan Adopted by the Board of Directors: April 16, 2015 Approved by the Stockholders: June 8, 2015 Amended by the Board of Directors: March 21, 2016 Amendment Approved by the Stockholders: May 18, 2016 Amended by the Board of Directors: April 10, 2017 A
Read more →TVTXChris Cline, CFA Senior Director, Investor Relations 646-630-7519 IR@retrophin.com Retrophin Provides Corporate Update and 2017 Preview FDA discussions on sparsentan planned for January; RE-024 advancing with Ph
Senior Director, Investor Relations Retrophin Provides Corporate Update and 2017 Preview FDA discussions on sparsentan planned for January; RE-024 advancing with Phase 3 trial for the treatment of PKAN Preliminary Full-Year 2016 Revenue of Approximately $134 Million SAN DIEGO
Read more →TVTXChris Cline, CFA Senior Director, Investor Relations 646-564-3680 IR@retrophin.com Retrophin Appoints Roy D. Baynes, M.D., Ph.D., to Board of Directors SAN DIEGO (
Senior Director, Investor Relations Roy D. Baynes, M.D., Ph.D., to Board of Directors SAN DIEGO (July 19, 2016) Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Roy D. Baynes, M.D., Ph.D., to its Board of Directors, effective immediately. Dr. Baynes currently
Read more →TVTXR ETROPHIN , I NC . 2015 E QUITY I NCENTIVE P LAN A DOPTED BY THE B OARD OF D IRECTORS : A PRIL 16, 2015 A PPROVED BY THE S TOCKHOLDERS : J UNE 8, 2015 A MENDED BY THE B OARD OF D IRECTORS : M ARCH 21, 2016 A MENDMENT A
2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APPROVED BY THE STOCKHOLDERS: AMENDED BY THE BOARD OF DIRECTORS: MARCH 21, 2016 AMENDMENT APPROVED BY THE STOCKHOLDERS: MAY 18, 2016 (a) Successor to and Continuation of Prior Plan. The Plan is intended as the s
Read more →TVTXChris Cline, CFA Senior Director, Investor Relations 646-564-3680 IR@retrophin.com Retrophin Reports First Quarter 2016 Financial Results First quarter revenues increased 67 percent year-ov
Senior Director, Investor Relations First Quarter 2016 Financial Results First quarter revenues increased 67 percent year-over-year Enrollment of the Phase 2 DUET study of sparsentan completed; top-line results expected third quarter 2016 SAN DIEGO (May 3, 2016) Retrophin, In
Read more →TVTXChris Cline, CFA Director, Investor Relations 646-564-3680 IR@retrophin.com Retrophin Reports Fourth Quarter and Full Year 2015 Financial Results Full year 2016 revenues projected to be $13
Director, Investor Relations Fourth Quarter and Full Year 2015 Financial Results Full year 2016 revenues projected to be $130.0 to $140.0 million Top-line data from sparsentan Phase 2 DUET study expected 3Q16 Clinical trial evaluating efficacy of RE-024 in PKAN to initiate in
Read more →TVTXRETIREMENT AND TRANSITION AGREEMENT This RETIREMENT AND TRANSITION AGREEMENT ( Agreement ) is effective as of the last date signed by the parties hereto (the Effective Date ) and is entered into by and between RETROPHIN,
RETIREMENT AND TRANSITION AGREEMENT This RETIREMENT AND TRANSITION AGREEMENT ( Agreement ) is effective as of the last date signed by the parties hereto (the Effective Date ) and is entered into by and between RETROPHIN, INC., a Delaware corporation (the Company ) and MARGARET
Read more →TVTXRetrophin, Inc. Chris Cline, CFA Director, Investor Relations 646-564-3680 IR@retrophin.com Retrophin Announces Preliminary Full-Year 2015 Revenue of Approximately $99.9 Million SAN DIEGO (
Director, Investor Relations Retrophin Announces Preliminary Full-Year 2015 Revenue of Approximately $99.9 Million (January 11, 2016) Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary, and unaudited financial data, the Company expects net product sales
Read more →TVTXRetrophin, Inc. Chris Cline, CFA Director, Investor Relations 646-564-3680 IR@retrophin.com Retrophin Reports Third Quarter 2015 Financial Results Third quarter revenue of $28.0 million marks sixth consecutive q
Director, Investor Relations Retrophin Reports Third Quarter 2015 Financial Results Third quarter revenue of $28.0 million marks sixth consecutive quarter of growth SAN DIEGO (November 3, 2015) Retrophin, Inc. (NASDAQ: RTRX) today reported its third quarter 2015 financial resu
Read more →TVTXUNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK X Retrophin, Inc., : : Case No. Plaintiff, : : v. : COMPLAINT : Martin Shkreli, : : Defendant. : X Retrophin, Inc. ( Retrophin or the Company ), by its counsel C
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK X Retrophin, Inc., : : Case No. Plaintiff, : : v. : COMPLAINT : Martin Shkreli, : : Defendant. : X Retrophin, Inc. ( Retrophin or the Company ),
Read more →TVTXRetrophin, Inc. Chris Cline, CFA Director, Investor Relations 646-564-3680 IR@retrophin.com Retrophin Reports Second Quarter 2015 Financial Results Second quarter revenue of $24.1 million Full year 2015 revenue
Director, Investor Relations Retrophin Reports Second Quarter 2015 Financial Results Second quarter revenue of $24.1 million Full year 2015 revenue projected to be $95 to $100 million SAN DIEGO (August 4, 2015) Retrophin, Inc. (NASDAQ: RTRX) today reported its second quarter
Read more →TVTXRetrophin, Inc. Executive/Designated Officer Annual Bonus Plan Plan Objective The purpose of the Retrophin, Inc. Executive Officer Bonus Plan (the Plan ) is to provide incentives to and reward named executive officers an
2015 Retrophin, Inc. Executive/Designated Officer Annual Bonus Plan The purpose of the Retrophin, Inc. Executive Officer Bonus Plan (the Plan ) is to provide incentives to and reward named executive officers and designated officers of Retrophin, Inc. (the Company ) (each a Par
Read more →TVTXR ETROPHIN , I NC . 2015 E QUITY I NCENTIVE P LAN A DOPTED BY THE B OARD OF D IRECTORS : A PRIL 16, 2015 A PPROVED BY THE S TOCKHOLDERS : J UNE 8, 2015 1. General. (a) Successor to and Continuation of Prior Plan. The Pla
2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APPROVED BY THE STOCKHOLDERS: (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Retrophin, Inc. 2014 Incentive Compensation Plan (the Prior Plan ). Fo
Read more →TVTXRetrophin, Inc. Chris Cline, CFA Manager, Investor Relations 646-564-3680 IR@retrophin.com Retrophin Reports First Quarter 2015 Financial Results First quarter revenues increased 23% sequentially to $17.4 millio
Manager, Investor Relations Retrophin Reports First Quarter 2015 Financial Results First quarter revenues increased 23% sequentially to $17.4 million Cholbam received FDA approval; launch underway SAN DIEGO (May 11, 2015) Retrophin, Inc. (NASDAQ: RTRX) today reported its firs
Read more →TVTXRetrophin, Inc. Chris Cline, CFA Manager, Investor Relations 646-564-3680 IR@retrophin.com Retrophin s Board of Directors Appoints John W. Kozarich, Ph.D. as Independent Director and Names Jeffrey A. Meckler as
Manager, Investor Relations Retrophin s Board of Directors Appoints John W. Kozarich, Ph.D. as Independent Director and Names Jeffrey A. Meckler as Chairman SAN DIEGO (April 1, 2015) Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Dr. John W. Kozarich to the
Read more →Competitive Position
How TVTX ranks across every disease it competes inCompetitive Position is a premium feature
See how TVTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial